The outlook of companies tied to Sildenafil's past presents a challenging investment picture . While the initial surge generated substantial returns , generic copies have significantly eroded market share . Investing in associated pharmaceutical businesses now requires a careful assessment of patent protection , evolving patient shifts , and the po